Literature DB >> 16798220

Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication?

Shin-ichi Takeda1, Yasunobu Funakoshi, Yoshihisa Kadota, Masaru Koma, Hajime Maeda, Satoko Kawamura, Yoko Matsubara.   

Abstract

BACKGROUND: Pulmonary resection after induction therapy is associated with high rates of pulmonary morbidity and mortality. However, the impact of induction therapy on the pulmonary toxicity and associated pulmonary complications has not been fully investigated in the setting of lung cancer surgery.
METHODS: We assessed the 66 consecutive patients who underwent a pulmonary resection after induction therapy, 48 of whom received chemoradiotherapy and 18, chemotherapy alone. Results of pulmonary function before and after induction therapy were compared, and logistic regression analyses utilized to explore the risk factors of pulmonary morbidity.
RESULTS: After induction therapy, forced expiratory volume in 1 second (FEV1) was increased significantly (from 2.28 +/- 0.61 L to 2.40 +/- 0.62 L; p < 0.05); however, percent vital capacity (%VC) and FEV1/FVC did not change significantly. The diffusing capacity of lung for carbon monoxide (D(LCO)) was decreased significantly by 21% (from 90.3% +/- 18.3% to 71.1% +/- 12.5%; p < 0.0005). Patients with respiratory complication showed lower predicted postoperative %FEV1 (49.5% +/- 11.1% versus 57.2% +/- 14.2%; p = 0.031) and predicted postoperative %Dlco (41.9% +/- 8.0% versus 55.4% +/- 10.1%; p < 0.0001) results than those without complications. Univariate and multivariate analyses revealed that predicted postoperative %D(LCO) alone was an independent factor to predict postoperative pulmonary morbidity.
CONCLUSIONS: For patients who undergo a pulmonary resection after induction therapy, predicted postoperative %D(LCO) is more important to predict pulmonary morbidity rather than static pulmonary function (predicted postoperative %VC or %FEV1). The decrease in D(LCO) is thought to reflect a limited gas exchange reserve, caused by the potential toxicity of chemotherapy or chemoradiotherapy. We believe that the impact of diffusion limitation after induction therapy should to be emphasized to decrease the pulmonary morbidity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16798220     DOI: 10.1016/j.athoracsur.2006.01.045

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer.

Authors:  Jose L Lopez Guerra; Daniel R Gomez; Yan Zhuang; Lawrence B Levy; George Eapen; Hongmei Liu; Radhe Mohan; Ritsuko Komaki; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-13       Impact factor: 7.038

Review 2.  Clinical pathway for thoracic surgery in the United States.

Authors:  Benjamin Wei; Robert J Cerfolio
Journal:  J Thorac Dis       Date:  2016-02       Impact factor: 2.895

Review 3.  Preoperative functional workup for patients with advanced lung cancer.

Authors:  Alessandro Brunelli
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

4.  Airway bacterial colonization in patients with non-small cell lung cancer and the alterations during the perioperative period.

Authors:  Jiandong Mei; Lunxu Liu; Menglin Tang; Ninghui Xu; Qiang Pu; Chengwu Liu; Lin Ma; Hui Shi; Guowei Che
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

5.  Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer.

Authors:  Jose Luis Lopez Guerra; Daniel Gomez; Yan Zhuang; Lawrence B Levy; George Eapen; Hongmei Liu; Radhe Mohan; Ritsuko Komaki; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-01       Impact factor: 7.038

6.  Comparison of pulmonary function changes between patients receiving neoadjuvant chemotherapy and chemoradiotherapy prior to minimally invasive esophagectomy: a randomized and controlled trial.

Authors:  Xiaosang Chen; Mingjun Du; Han Tang; Hao Wang; Yong Fang; Miao Lin; Jun Yin; Lijie Tan; Yaxing Shen
Journal:  Langenbecks Arch Surg       Date:  2022-08-25       Impact factor: 2.895

7.  Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.

Authors:  James G Connolly; Megan Fiasconaro; Kay See Tan; Michael A Cirelli; Gregory D Jones; Raul Caso; Daniel E Mansour; Joseph Dycoco; Jae Seong No; Daniela Molena; James M Isbell; Bernard J Park; Matthew J Bott; David R Jones; Gaetano Rocco
Journal:  J Thorac Cardiovasc Surg       Date:  2021-12-23       Impact factor: 6.439

8.  Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease.

Authors:  Michael B Drummond; Pamela F Schwartz; William T Duggan; John G Teeter; Richard J Riese; Richard C Ahrens; Robert O Crapo; Richard D England; Neil R Macintyre; Robert L Jensen; Robert A Wise
Journal:  Am J Respir Crit Care Med       Date:  2008-05-08       Impact factor: 21.405

9.  Lung function changes after chemoradiation therapy in patients with lung cancer treated by three usual platinum combinations.

Authors:  Vasilios Mihailidis; Stavros Anevlavis; Georgia Karpathiou; George Kouliatsis; Argyrios Tzouvelekis; Paul Zarogoulidis; Paschalis Ntolios; Paschalis Steiropoulos; Demosthenes Bouros; Marios E Froudarakis
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

10.  The effect of selective internal radiation therapy with yttrium-90 resin microspheres on lung carbon monoxide diffusion capacity.

Authors:  Tunc Ones; Emel Eryuksel; Feyyaz Baltacioglu; Berrin Ceyhan; Tanju Yusuf Erdil
Journal:  EJNMMI Res       Date:  2017-12-29       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.